Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 4/20 | 0.40 |
| ▸ | CHUK | O15111 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 7/20 | 0.38 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | KIT | P10721 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.33 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.33 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17407762 | 0.83 | CHUK (0.40) | KIF11CHUKCHEK1KIT | |
| SCHEMBL18858401 | 0.80 | KIF11 (0.64) | KIF11CHUKGABRA1GABRG2GABRB3 | |
| SCHEMBL17359744 | 0.80 | CHUK (0.56) | KIF11CHUK | |
| SCHEMBL12395870 | 0.76 | CHEK1 (0.63) | CHUKCHEK1 | |
| SCHEMBL17358501 | 0.75 | KIF11 (0.65) | KIF11CHUK | |
| SCHEMBL8325679 | 0.74 | EGFR (0.40) | KIF11CHUKAGBL2KIT | |
| SCHEMBL12395872 | 0.70 | CHEK1 (0.63) | CHEK1GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL30720002 | 0.69 | AGBL2 (0.46) | AGBL2 | |
| SCHEMBL29153656 | 0.69 | AGBL2 (0.46) | AGBL2 | |
| SCHEMBL16626017 | 0.68 | MET (0.44) | AGBL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9994577-B2 | Azepanyl-derivatives and pharmaceutical compositions comprising the same with antiparasitic activity | MERCK PATENT GMBH (DE) | 2018-06-12 | — | — | US | disclosed |
| US-20170137428-A1 | AZEPANYL-DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME WITH ANTIPARASITIC ACTIVITY | MERCK PATENT GMBH (DE) | 2017-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137428-A1 | AZEPANYL-DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME WITH ANTIPARASITIC ACTIVITY | ACHE, PARK7, CYP51A1 | KIF11 1584/4885CHUK 4243/4885CHEK1 4761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.